Adverse reactions of Niaoduqing granules: A systematic review and meta-analysis

Fu, Baohui; Shang, Zongjie; Song, Simian; Xu, Yupei; Wei, Lijuan; Li, Ge

doi:10.1016/j.phymed.2022.154535

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, under the circumstance (12,58). In terms of safety, no significance could be found between the intervention and control group, consistently with a previous review (59). Therefore, it is suggested that NDQ granules has potential in suppressing inflammation and preserving renal function under DKD.…”

Section: Discussionsupporting

confidence: 82%

Effects of Niaoduqing granules on inflammatory response of diabetic kidney disease: A meta‑analysis

Zhou,

Hao,

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is one of the most severe chronic microvascular complications of diabetes and the leading cause of end-stage kidney disease worldwide. The mechanism of inflammation underlying DKD has been attracting attention over recent years, but effective therapeutic strategies have remained elusive. Niaoduqing (NDQ) granules are one of the most commonly used drugs for the treatment of DKD in China, and it has therapeutic effects against inflammation in DKD. Therefore, the aim of the present analysis was to evaluate the inflammatory response outcomes and safety of NDQ granules for the treatment of DKD. The following databases were searched from their inception to 31st of May 2023 to obtain published accounts of relevant randomized controlled trials: China National Knowledge Infrastructure, China Science and Technology Journal, Wanfang, The Chinese Biomedicine, PubMed, Web of Science and Cochrane Library. The 'risk of bias' evaluation tool produced by the Cochrane Collaboration Handbook was used for evaluating the quality, whereas Revman software (version 5.3) was used for meta-analysis. In total, 16 studies were included into the present study according to criteria, with a total of 1,526 patients. Compared with those in the control group, the results of the meta-analysis revealed that the combination of conventional treatment and NDQ granules may further decrease C-reactive protein [standardized mean difference (SMD), -1.33; 95% confidence interval (CI), -1.76, -0.91; P<0.00001], TNF-α (SMD, -1.90; 95% CI, -2.35,-1.45; P<0.00001) and IL-6 (SMD, -1.72; 95% CI, -2.52,-0.91; P<0.0001) levels, whilst increasing the clinical effective rate (risk ratio, 1.22; 95% CI, 1.14,1.29; P<0.00001), in patients with DKD. In terms of safety, a total of 34 and 39 patients included in the intervention and in the control group, respectively, developed adverse reactions. Results from the present analysis suggest that NDQ granules may be beneficial in suppressing inflammation caused by DKD when used in combination with conventional treatment, potentially guiding future directions in clinical practice. However, further high-quality studies are needed to confirm the anti-inflammation response in the future.

show abstract

Section: Discussionsupporting

confidence: 82%

Effects of Niaoduqing granules on inflammatory response of diabetic kidney disease: A meta‑analysis

Zhou,

Hao,

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Many Chinese herbal compound preparations, including Yiqi Jiedu Huayu Decoction, Keluoxin capsule, and many others mentioned above, have been used in China for thousands of years. In consideration of objective factors such as the mixing of ingredients in Chinese herbal compound preparations, researchers in recent years have attempted to elucidate the mechanism of action of Chinese herbal compound preparations by isolating the active ingredients and conducting cellular or animal experiments (190,191).…”

Section: Discussionmentioning

confidence: 99%

Chinese herbal medicine and its active compounds in attenuating renal injury via regulating autophagy in diabetic kidney disease

et al. 2023

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is the main cause of end-stage renal disease worldwide, and there is a lack of effective treatment strategies. Autophagy is a highly conserved lysosomal degradation process that maintains homeostasis and energy balance by removing protein aggregates and damaged organelles. Increasing evidence suggests that dysregulated autophagy may contribute to glomerular and tubulointerstitial lesions in the kidney under diabetic conditions. Emerging studies have shown that Chinese herbal medicine and its active compounds may ameliorate diabetic kidney injury by regulating autophagy. In this review, we summarize that dysregulation or insufficiency of autophagy in renal cells, including podocytes, glomerular mesangial cells, and proximal tubular epithelial cells, is a key mechanism for the development of DKD, and focus on the protective effects of Chinese herbal medicine and its active compounds. Moreover, we systematically reviewed the mechanism of autophagy in DKD regulated by Chinese herb compound preparations, single herb and active compounds, so as to provide new drug candidates for clinical treatment of DKD. Finally, we also reviewed the candidate targets of Chinese herbal medicine regulating autophagy for DKD. Therefore, further research on Chinese herbal medicine with autophagy regulation and their targets is of great significance for the realization of new targeted therapies for DKD.

show abstract

“…Through network pharmacology, it has been found that the mechanism of Niaoduqing granules in treating DN proteinuria is to inhibit the activity of the AGE/RAGE pathway and the overexpression of VEGF-A, ICAM-2, PTGS-5, and ACE in MPC1 cells to prevent podocyte injury in DN [110]. However, evidence of adverse drug reactions remains unclear [111]. An ESRD rat model confirmed that Niaoduqing granules improved renal fibrosis and urinary protein excretion by regulating the p38 MAPK/NF-κB signaling pathway [112].…”

Section: Other Chinese Patent Medicinementioning

confidence: 99%

Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective

Zhang,

Wang,

Zhou

et al. 2023

Preprint

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease worldwide and significantly increases the risk of premature death due to cardiovascular diseases. Elevated urinary albumin levels are an important clinical feature of DKD. Effective control of albuminuria not only delays glomerular filtration rate (GFR) decline but also markedly reduces cardiovascular disease risk and all-cause mortality. New drugs for treating DKD proteinuria, including sodium-glucose cotransporter 2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists (MRAs), and endothelin receptor antagonists (REAs), have shown significant efficacy. Auxiliary treatment with proprietary Chinese medicine has also yielded promising results; however, it also faces a broader scope for development. The mechanisms by which these drugs treat albuminuria in patients with DKD should be described more thoroughly. The positive effects of combination therapy with two or more drugs in reducing albuminuria and protecting the kidneys warrant further investigation. Therefore, this review explores the pathophysiological mechanism of albuminuria in patients with DKD, the value of clinical diagnosis and prognosis, new progress and mechanisms of treatment, and multidrug therapy in patients who have type 2 diabetic kidney disease (T2DKD), providing a new perspective on the clinical diagnosis and treatment of DKD.

show abstract

Adverse reactions of Niaoduqing granules: A systematic review and meta-analysis

Cited by 5 publications

References 32 publications

Effects of Niaoduqing granules on inflammatory response of diabetic kidney disease: A meta‑analysis

Effects of Niaoduqing granules on inflammatory response of diabetic kidney disease: A meta‑analysis

Chinese herbal medicine and its active compounds in attenuating renal injury via regulating autophagy in diabetic kidney disease

Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective

Contact Info

Product

Resources

About